Merck's Keytruda Combo Trial Meets Overall Survival Endpoint In PD-L1 Expressing Breast Cancer Patients

Merck & Co Inc MRK has announced overall survival (OS) results from Phase 3 KEYNOTE-355 trial evaluating Keytruda (pembrolizumab) in combination with chemotherapy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC).
Final analysis show first-line treatment with Keytruda/Chemo combo demonstrated a statistically significant and clinically meaningful improvement in OS compared with chemotherapy alone in patients with mTNBC whose tumors expressed PD-L1.
No new safety signals were identified.
These OS results will be presented at an upcoming medical meeting and submitted to regulatory authorities.
The FDA also approved Keytruda - Chemo combo in early-stage triple-negative breast cancer patients at high risk.
Price Action: MRK shares are up 0.01% at $77.25 during the premarket session on the last check Tuesday.

Momentum16.06

Growth87.86

Quality51.51

Value43.81

Short

Medium

Long